Immunome Submits NDA for Varegacestat in Desmoid Tumors After Positive Phase 3 RINGSIDE Trial
Apr 29, 2026
Immunome submitted an NDA to the FDA for varegacestat in desmoid tumors after the Phase 3 RINGSIDE trial showed an 84% reduction in progression risk (HR=0.16) and a 56% objective response rate. The company plans to file in Q2 2026.